← Back to Calendar
Live Company Data
NMS
Updated
just now
· Data: FMP
Current Price
$342.50
+913.61%
+$308.71 today
Day: $324.87 – $346.35
Market Cap
N/A
Shares out: 27.85M
Float: 25.78M
52-Week Range
Current price is at 96% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs)
Key Notes
NDA accepted with Priority Review. PDUFA September 27, 2026 (confirmed by FDA March 30, 2026). EMBOLD registrational cohort data: relutrigine demonstrated 46–53% placebo-adjusted seizure reductions in SCN2A/SCN8A-DEEs. NaV1.6/NaV1.2 sodium channel inhibitor — precision target for gain-of-function mutations in these rare pediatric epilepsies. Second NDA from Praxis alongside ulixacaltamide (ET). EMERALD Phase 3 in broader DEEs also ongoing. Rare Pediatric Disease designation makes company eligible for PRV.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.